⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LGVN News
Longeveron Inc. Common Stock
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
globenewswire.com
LGVN
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
globenewswire.com
LGVN
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
LGVN
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
globenewswire.com
LGVN
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
globenewswire.com
LGVN
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
globenewswire.com
LGVN
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
globenewswire.com
LGVN